Amicus Therapeutics Narrows Q1 Loss as Revenue Climbs
07:59 AM EDT, 05/10/2021 (MT Newswires) -- Amicus Therapeutics (FOLD) said Monday it narrowed its Q1 net loss to $0.25 per diluted share from a loss of $0.35 a year earlier. Analysts polled by Capital IQ estimated a loss of $0.24 per share.
Net product sales for the quarter reached $66.4 million, up from $60.5 million a year ago. Analysts polled by Capital IQ expected $71.8 million.
Looking ahead, the company said it expects total revenue of $300 million to $315 million for Galafold, an oral therapy for Fabry disease, for the full year of 2021.
Price: 9.75, Change: 0.00, Percent Change: 0.00